- Home
- BRFS vs RYTM Comparison
BRFS vs RYTM Comparison
Compare BRFS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRFS
- RYTM
- Stock Information
- Founded
- BRFS 1934
- RYTM 2008
- Country
- BRFS Brazil
- RYTM United States
- Employees
- BRFS N/A
- RYTM N/A
- Industry
- BRFS Meat/Poultry/Fish
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BRFS Consumer Staples
- RYTM Health Care
- Exchange
- BRFS Nasdaq
- RYTM Nasdaq
- Market Cap
- BRFS 5.6B
- RYTM 5.9B
- IPO Year
- BRFS 2000
- RYTM 2017
- Fundamental
- Price
- BRFS $3.58
- RYTM $92.99
- Analyst Decision
- BRFS Hold
- RYTM Strong Buy
- Analyst Count
- BRFS 2
- RYTM 13
- Target Price
- BRFS $13.75
- RYTM $101.92
- AVG Volume (30 Days)
- BRFS 2.4M
- RYTM 608.2K
- Earning Date
- BRFS 08-18-2025
- RYTM 08-05-2025
- Dividend Yield
- BRFS 2.45%
- RYTM N/A
- EPS Growth
- BRFS N/A
- RYTM N/A
- EPS
- BRFS 0.41
- RYTM N/A
- Revenue
- BRFS $11,077,622,712.00
- RYTM $156,287,000.00
- Revenue This Year
- BRFS $9.21
- RYTM $37.86
- Revenue Next Year
- BRFS $5.06
- RYTM $72.72
- P/E Ratio
- BRFS $8.55
- RYTM N/A
- Revenue Growth
- BRFS 18.02
- RYTM 53.55
- 52 Week Low
- BRFS $2.99
- RYTM $42.92
- 52 Week High
- BRFS $4.87
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- BRFS 49.23
- RYTM 69.05
- Support Level
- BRFS $3.44
- RYTM $85.73
- Resistance Level
- BRFS $3.83
- RYTM $90.40
- Average True Range (ATR)
- BRFS 0.12
- RYTM 2.80
- MACD
- BRFS -0.02
- RYTM -0.33
- Stochastic Oscillator
- BRFS 43.75
- RYTM 87.14
About BRFS BRF S.A.
BRF SA is an international producer of fresh and frozen protein foods. It operates by raising, producing, and slaughtering poultry and pork for processing, production, and sale of fresh meat, processed products, pasta, margarine, pet food, and others. The Company holds as its main brands Sadia, Perdigao, Qualy, Chester, Kidelli, Perdix, Banvit, Biofresh, and Gran Plus, present mainly in Brazil, Turkey, and Middle Eastern countries. The group has three reportable segments, being; Brazil, International, and Other segments.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.